Research programme: antiemetic and antinauseant therapeutic - Sumitomo Dainippon Pharma/Maruishi Pharmaceutical

Drug Profile

Research programme: antiemetic and antinauseant therapeutic - Sumitomo Dainippon Pharma/Maruishi Pharmaceutical

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sumitomo Dainippon Pharma
  • Developer Maruishi Pharmaceutical; Sumitomo Dainippon Pharma
  • Class
  • Mechanism of Action Fatty acid amide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Nausea and vomiting

Most Recent Events

  • 06 Sep 2017 Sumitomo Dainippon Pharma and Maruishi Pharmaceutical enter into an agreement for the development and commercialisation of a candidate for Nausea and vomiting
  • 06 Sep 2017 Preclinical trials in Nausea and vomiting in USA, Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top